: Metformin recently has been known to be able to regulate the AMPK/mTOR pathway and be able to regulate several autoimmune, inflammation, malignant and aging related conditions. This study aims to evaluate the effect of intraperitoneal versus oral metformin on IL-17 levels on a pristane induce female BALB/c mice. Thirty-one female BALB/c mice, aged 6 weeks and weighted approximately 25 grams, induced with 0.5 ml of pristane (2,6,10,14 tetramethylpentadecane, TMPD) intraperitoneally. After 120 days, treatment group given normal saline 100 mcl, oral metformin 100mg/kgBW, or intraperitoneal metformin 100mg/kgBW. After 60 days of treatment, all treatment groups were sacrificed, and kidney specimens prepared and stained using H&E. Interleukin-17 level was measured using ELISA. Results - Post induction with intraperitoneal pristane, there was a difference in IL-17 level between normal control and SLE model groups (52.33 vs. 64.20 pg/mL; mean difference 11.87 pg/mL; 95% CI 8.93 – 14.81 pg/mL; p<0.001). Comparison between normal saline control with oral metformin group resulted in IL-17 levels of 64.62 vs. 60.30 pg/mL (mean difference 4.31 pg/mL; 95% CI 0.83-7.79; p=0.021). Comparison between normal saline control with intraperitoneal metformin group resulted in IL-17 levels of 64.62 vs. 55.04 pg/mL (mean difference 9.57 pg/mL; 95% CI 4.17-14.97 pg/mL; p=0.004). Metformin is a potential new therapy to reduce the levels of IL-17 in SLE and in turn, inhibits the development of glomerulonephritis. Intraperitoneal metformin, or intravenous in human, could provide a novel route of administration to improve the effect of metformin on lupus patients.